Kindler also lured Neil Gibson, formerly chief scientific officer at biotech OSI Pharmaceuticals, to head oncology research, and Briggs Morrison, a former oncologist who made clinical trials run faster at Merck, to design drug studies.

FORBES: Magazine Article

Kindler also lured Neil Gibson, formerly chief scientific officer at biotech OSI Pharmaceuticals, to head oncology research, and Briggs Morrison, a former oncologist who made clinical trials run faster at Merck (nyse: MRK - news - people ), to design drug studies.

FORBES: Can Cancer Cure Pfizer?